ReviewMedical gas research2026
Photodynamic therapy: research progress and paradigm evolution from mechanism innovation to clinical breakthrough in cancers.
Review in Medical gas research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy is a noninvasive anticancer treatment that uses light-activated photosensitizers to generate reactive oxygen species. However, its clinical efficacy is severely limited by tumor hypoxia and rapid oxygen depletion during the type II photochemical reaction. To address these challenges, we synthesized data from randomized controlled trials and meta-analyses published between 2000 and 2025. Our review shows that photodynamic therapy significantly increases survival rates in patients with malignant pleural effusion and achieves high complete response rates in patients with esophageal and gastric cancers. However, a risk-of-bias assessment reveals limitations in study design regarding blinding and sample size. Crucially, we identify gas-mediated therapies as the next paradigm shift. This review discusses emerging strategies to overcome tumor hypoxia and improve the efficacy of photodynamic therapy. These strategies include oxygen-generating nanoplatforms, tumor microenvironment modulation, and combination approaches with chemotherapy, radiotherapy, and immunotherapy. Additionally, we discuss the critical role of sequential immunotherapy and propose standardized dosimetry protocols that report irradiance and drug-light intervals. These protocols aim to facilitate global regulatory harmonization and clinical reproducibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.